Literature DB >> 17906291

DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease.

Soo-Ryoon Ryoo1, Hey Kyeong Jeong, Chinzorig Radnaabazar, Jin-Ju Yoo, Hyun-Jeong Cho, Hye-Won Lee, In-Sook Kim, Young-Hee Cheon, Young Soo Ahn, Sul-Hee Chung, Woo-Joo Song.   

Abstract

Most individuals with Down syndrome show early onset of Alzheimer disease (AD), resulting from the extra copy of chromosome 21. Located on this chromosome is a gene that encodes the dual specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). One of the pathological hallmarks in AD is the presence of neurofibrillary tangles (NFTs), which are insoluble deposits that consist of abnormally hyperphosphorylated Tau. Previously it was reported that Tau at the Thr-212 residue was phosphorylated by Dyrk1A in vitro. To determine the physiological significance of this phosphorylation, an analysis was made of the amount of phospho-Thr-212-Tau (pT212) in the brains of transgenic mice that overexpress the human DYRK1A protein (DYRK1A TG mice) that we recently generated. A significant increase in the amount of pT212 was found in the brains of DYRK1A transgenic mice when compared with age-matched littermate controls. We further examined whether Dyrk1A phosphorylates other Tau residues that are implicated in NFTs. We found that Dyrk1A also phosphorylates Tau at Ser-202 and Ser-404 in vitro. Phosphorylation by Dyrk1A strongly inhibited the ability of Tau to promote microtubule assembly. Following this, using mammalian cells and DYRK1A TG mouse brains, it was demonstrated that the amounts of phospho-Ser-202-Tau and phospho-Ser-404-Tau are enhanced when DYRK1A amounts are high. These results provide the first in vivo evidence for a physiological role of DYRK1A in the hyperphosphorylation of Tau and suggest that the extra copy of the DYRK1A gene contributes to the early onset of AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906291     DOI: 10.1074/jbc.M707358200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  94 in total

1.  Survival and morbidity outcomes for very low birth weight infants with Down syndrome.

Authors:  Nansi S Boghossian; Nellie I Hansen; Edward F Bell; Barbara J Stoll; Jeffrey C Murray; Abbot R Laptook; Seetha Shankaran; Michele C Walsh; Abhik Das; Rosemary D Higgins
Journal:  Pediatrics       Date:  2010-11-22       Impact factor: 7.124

2.  The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.

Authors:  Jerzy Wegiel; Karol Dowjat; Wojciech Kaczmarski; Izabela Kuchna; Krzysztof Nowicki; Janusz Frackowiak; Bozena Mazur Kolecka; Jarek Wegiel; Wayne P Silverman; Barry Reisberg; Mony Deleon; Thomas Wisniewski; Cheng-Xin Gong; Fei Liu; Tatyana Adayev; Mo-Chou Chen-Hwang; Yu-Wen Hwang
Journal:  Acta Neuropathol       Date:  2008-08-12       Impact factor: 17.088

3.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

4.  Nonprimed and DYRK1A-primed GSK3 beta-phosphorylation sites on MAP1B regulate microtubule dynamics in growing axons.

Authors:  Timothy M E Scales; Shen Lin; Michaela Kraus; Robert G Goold; Phillip R Gordon-Weeks
Journal:  J Cell Sci       Date:  2009-06-23       Impact factor: 5.285

5.  Novel screening cascade identifies MKK4 as key kinase regulating Tau phosphorylation at Ser422.

Authors:  Fiona Grueninger; Bernd Bohrmann; Klaus Christensen; Martin Graf; Doris Roth; Christian Czech
Journal:  Mol Cell Biochem       Date:  2011-06-03       Impact factor: 3.396

6.  Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.

Authors:  Nana Jin; Xiaomin Yin; Jianlan Gu; Xinhua Zhang; Jianhua Shi; Wei Qian; Yuhua Ji; Maohong Cao; Xiaosong Gu; Fei Ding; Khalid Iqbal; Cheng-Xin Gong; Fei Liu
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

7.  Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).

Authors:  Bryan T Mott; Cordelle Tanega; Min Shen; David J Maloney; Paul Shinn; William Leister; Juan J Marugan; James Inglese; Christopher P Austin; Tom Misteli; Douglas S Auld; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2009-10-03       Impact factor: 2.823

8.  DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort.

Authors:  José Luis Vázquez-Higuera; Pascual Sánchez-Juan; Eloy Rodríguez-Rodríguez; Ignacio Mateo; Ana Pozueta; Ana Frank; Isabel Sastre; Fernando Valdivieso; José Berciano; María J Bullido; Onofre Combarros
Journal:  BMC Med Genet       Date:  2009-12-08       Impact factor: 2.103

9.  Development of a sensitive non-radioactive protein kinase assay and its application for detecting DYRK activity in Xenopus laevis oocytes.

Authors:  Eva Lilienthal; Katharina Kolanowski; Walter Becker
Journal:  BMC Biochem       Date:  2010-05-20       Impact factor: 4.059

10.  High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation.

Authors:  David O Azorsa; RiLee H Robeson; Danielle Frost; Bessie Meec hoovet; Gillian R Brautigam; Chad Dickey; Christian Beaudry; Gargi D Basu; David R Holz; Joseph A Hernandez; Kristen M Bisanz; Leslie Gwinn; Andrew Grover; Joseph Rogers; Eric M Reiman; Michael Hutton; Dietrich A Stephan; Spyro Mousses; Travis Dunckley
Journal:  BMC Genomics       Date:  2010-01-12       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.